We are a start up biotech focused on meeting the need for new diagnostics, therapeutics and or vaccines against infectious , rare genetic and immune diseasess that preferentially affect the people(s) of sub-Saharan Africa. We use genomics and related technologies to unveil molecular targets for the development of the next generation of interventions. Our most successful advanced prototypes include (i) a rapid diagnostic test (RDT) for ebola virus disease-EVD, (ii) HIV-1 gene therapy, (iii) TB LFT and Microfluidics rapid culture systems. With over 10 new molecular entities-NMEs in the offing, we aim to build a company net-worth of US$6-12 billion (premised on the market price of each NME of between US$600-to $1.2 billion)
Sign in to view moreView Restrizymes Biotherapeutics (U) LTD team members, milestones, financial details and documents.